What Are Digital Twins in Healthcare?

Digital twins represent a paradigm shift in how clinicians approach disease management, moving from reactive, population-based protocols to proactive, individualized care. A digital twin is a virtual replica of a physical system that is continuously updated with real-time data to mirror the state of the original system. In healthcare, this concept translates into a dynamic, individualized model of a patient’s biology and physiology. Unlike static electronic health records or population-based algorithms, a digital twin integrates heterogeneous data streams—continuous glucose monitor (CGM) readings, insulin pump logs, physical activity trackers, dietary logs, genomic profiles, and clinical lab results—to create a living, evolving simulation of the patient’s metabolic processes. This model can then be used to simulate the effects of different interventions, predict future health trajectories, and optimize treatment plans in a risk-free virtual environment.

The term "digital twin" was first popularized in engineering for aerospace and manufacturing, where it was used to monitor and optimize the performance of complex systems like jet engines and wind turbines. Its adoption in medicine has accelerated over the past decade, driven by advances in sensor technology, machine learning, and computational modeling. In diabetes care, digital twins offer a way to move beyond one-size-fits-all protocols toward truly personalized treatment strategies. By mimicking the complex interplay of glucose metabolism, insulin sensitivity, and lifestyle factors, these models enable clinicians to ask "what if" questions and receive data-driven answers before implementing changes in the real world. This capability is especially valuable in diabetes, where treatment decisions must account for hundreds of variables each day, from meal composition and exercise timing to stress, sleep, and illness.

The Diabetes Management Challenge and the Need for Personalization

Diabetes is a chronic metabolic disorder characterized by the body's inability to maintain glucose homeostasis. Type 1 diabetes results from autoimmune destruction of pancreatic beta cells, leading to absolute insulin deficiency, while type 2 diabetes involves progressive insulin resistance and relative insulin deficiency. Both forms require careful management to prevent acute complications like hypoglycemia and diabetic ketoacidosis, as well as long-term complications such as neuropathy, nephropathy, retinopathy, and cardiovascular disease.

Despite advances in insulin formulations, glucose monitoring technologies, and pharmacotherapy, achieving and maintaining glycemic targets remains elusive for a majority of patients. Studies show that fewer than 25% of adults with diabetes achieve combined targets for glycemic control, blood pressure, and cholesterol. This gap between recommended and actual outcomes highlights the limitations of current treatment frameworks. Conventional algorithms—such as insulin-dose calculators and bolus advisors—are derived from population averages and do not account for individual differences in insulin sensitivity, absorption rates, hormonal fluctuations, or lifestyle patterns. A digital twin addresses this limitation by building a personalized mathematical representation of the patient’s metabolic system that can adapt as conditions change.

Current Applications in Diabetes Treatment

Digital twin technology is already being tested and deployed in several diabetes research and clinical settings. One of the most advanced applications involves the use of the UVA/Padova metabolic simulator, an FDA-accepted digital twin for type 1 diabetes that models glucose regulation and supports development of artificial pancreas systems. This simulator has been instrumental in testing closed-loop insulin delivery algorithms before human trials, saving time and reducing risk. More recently, digital twins have been extended to type 2 diabetes by incorporating models of insulin resistance, beta-cell function, and the effects of oral medications such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists.

Commercial platforms like Tidepool Loop are beginning to integrate digital twin components that allow patients and clinicians to simulate how changes in carbohydrate intake, exercise, or insulin timing will affect blood glucose levels throughout the day. These tools leverage machine learning to personalize the model parameters based on historical data, so the simulation improves over time. Researchers have also shown that digital twins can predict nocturnal hypoglycemia with greater accuracy than conventional algorithms, enabling proactive alarms and dose adjustments. A recent study published in Diabetes Technology & Therapeutics demonstrated that a digital twin-based decision support system reduced time in hypoglycemia by 38% without increasing time in hyperglycemia, compared to standard therapy.

Type 1 Diabetes: Artificial Pancreas and Beyond

Digital twins for type 1 diabetes are the most mature, largely because the underlying physiology—an absolute lack of insulin with variable sensitivity—is well characterized and can be modeled with reasonable accuracy. The UVA/Padova simulator, accepted by the FDA as a substitute for animal trials, has been used to test the safety and efficacy of control algorithms for hybrid closed-loop systems. These systems combine a CGM, an insulin pump, and a control algorithm to automate insulin delivery. Digital twins allow developers to explore thousands of scenarios, including sensor errors, missed meals, and exercise-induced hypoglycemia, without putting patients at risk. Beyond closed-loop development, digital twins are being used to individualize basal rates, bolus ratios, and correction factors far more precisely than standard empirical adjustments. They can also simulate the effects of new insulin analogs, such as ultra-rapid-acting formulations, to predict optimal dosing profiles for specific patient populations.

Type 2 Diabetes: Oral Medications and Lifestyle Interventions

The application of digital twins to type 2 diabetes introduces additional complexity due to the interplay of insulin resistance, beta-cell dysfunction, incretin effects, and comorbidities such as obesity and fatty liver disease. Nevertheless, several research groups have developed digital twin models that incorporate these factors. For example, the DETECT program uses a combination of patient-reported data, wearable device streams, and clinical biomarkers to build a model that can simulate responses to metformin, sulfonylureas, SGLT2 inhibitors, GLP-1 receptor agonists, and lifestyle modifications such as diet and exercise. These models can predict which combination of therapies is likely to yield the best glycemic outcomes for a given patient, as well as identify the risk of side effects like hypoglycemia or gastrointestinal intolerance. A pilot study found that patients whose treatment was guided by digital twin simulations achieved a 0.7% greater reduction in HbA1c over 6 months compared to a standard care group, with fewer medication adjustments needed.

Benefits of Digital Twins for Diabetes Care

  • Personalization: Each digital twin is tailored to an individual’s unique physiology, lifestyle, and disease progression, enabling treatments that are fine-tuned rather than generalized. This is especially important in diabetes, where no two patients respond identically to the same therapy.
  • Predictive Insights: By simulating future glucose excursions, digital twins can forecast daily patterns, identify windows of high risk for hypoglycemia or hyperglycemia, and recommend preemptive adjustments to insulin or diet. These predictions can also be used to alert patients and caregivers to dangerous situations before they develop.
  • Risk Reduction: Virtual testing of medication regimens, dose escalations, or new insulin formulations reduces the likelihood of adverse events by exposing only the model to potential harm. Clinicians can confidently test aggressive or novel strategies knowing that the patient will not experience unintended consequences.
  • Enhanced Patient Engagement: Interactive dashboards that show real-time model predictions and allow patients to experiment with lifestyle changes empower individuals to understand their condition better and adhere to treatment plans. When patients see how a healthy meal or a walk affects their simulated glucose curve, they gain tangible motivation to adopt healthier behaviors.
  • Efficient Clinical Trials: Digital twins can serve as virtual control arms or simulated patient cohorts, accelerating the evaluation of new therapies and reducing the size, cost, and duration of traditional trials. This approach has already been used in oncology and is gaining traction in endocrinology.
  • Reduced Clinical Burden: By automating the analysis of complex data sets and providing actionable recommendations, digital twins can save clinicians time and mental effort, allowing them to focus on higher-level clinical decision-making and patient counseling.

Technical and Clinical Challenges

Despite the promise, widespread adoption of digital twins for diabetes faces significant hurdles that must be addressed through continued research, development, and regulatory clarity.

Data Quality and Completeness

Models require high-fidelity, time-stamped data from multiple sources, and gaps or inaccuracies in CGM readings, meal logs, or activity levels can degrade model performance. Continuous glucose monitors are not always accurate during rapid glucose changes or in the presence of interfering substances such as acetaminophen. Meal logging requires patient compliance, which varies widely. Physical activity trackers may misclassify non-step activities like cycling or weightlifting. Furthermore, hormonal fluctuations due to the menstrual cycle, illness, or stress are difficult to capture but can dramatically affect glycemic control. Without complete and accurate data, a digital twin may produce simulations that diverge from reality, undermining trust in the technology.

Interoperability and Data Integration

Interoperability between devices and health IT systems is another barrier, as data from different manufacturers often use proprietary formats and protocols. A patient using a Dexcom CGM, an Omnipod insulin pump, an Apple Watch for activity tracking, and a MyFitnessPal app for diet logging may find it challenging to unify these data streams into a coherent model. Standards like HL7 FHIR are helping, but much work remains to create seamless data pipelines that can feed digital twin models in real time. Device manufacturers also have varying approaches to data access and privacy, which complicates the development of integrated digital twin platforms.

Computational and Regulatory Hurdles

Computational complexity means that running full physiological simulations in real time demands substantial processing power, which may not be available in all clinical settings. Training deep learning models on individual patient histories also requires powerful hardware and sophisticated software infrastructure. While cloud computing can address some of these challenges, it introduces latency and connectivity concerns—especially for patients in rural or underserved areas. Regulatory approval is still evolving; the FDA has published guidelines for digital health technologies but not yet specific pathways for digital twin-based decision support. Questions remain about what level of validation is required, how model updates should be managed, and whether digital twin recommendations require clinician oversight or can be delegated to automated algorithms.

Ethical Considerations

As with any data-driven tool, digital twins introduce ethical issues that must be addressed proactively to ensure equitable and responsible deployment.

Bias and Representativeness: Models built primarily on data from white, affluent populations may not accurately represent minority or underserved groups, potentially leading to inaccurate predictions and worsening health disparities. For example, insulin sensitivity varies by ethnicity, and dietary patterns differ by culture, yet many digital twin models are trained on homogeneous data sets. Developers must prioritize inclusive data collection and conduct fairness audits to ensure that digital twins serve all populations equitably.

Access and Equity: Access to digital twin technology could be limited by cost or required equipment, creating a two-tiered system of care. Patients who can afford CGMs, pumps, and smartwatches will benefit from personalized simulations, while those without such devices may be left behind. Policy interventions, such as insurance coverage and public health programs, are needed to ensure that digital twin technology does not exacerbate existing disparities.

Consent and Data Ownership: Patient consent for ongoing data collection and model use must be transparent, with clear options to opt out. Patients should understand what data is being collected, how it is used, who owns the digital twin, and what happens if they decide to leave the program. Data portability and the ability to delete a digital twin should also be guaranteed.

Clinician Training and Over-Reliance: Clinicians need training to interpret digital twin outputs critically, avoiding over-reliance on simulated predictions. A digital twin is a model, not a crystal ball, and its outputs are only as good as the data and assumptions that underpin it. Decision support systems should be designed to augment, not replace, clinical judgment. Medical education curricula must incorporate training on the strengths and limitations of digital twin technology.

Future Directions

The next generation of digital twins will incorporate real-time machine learning to adapt model parameters as new data streams in, creating a truly self-learning simulation. Integration with smart insulin pens, continuous ketone monitors, and wearable sensors for stress and sleep will enrich the model’s inputs and improve its predictive accuracy. Researchers are also exploring multiscale digital twins that bridge molecular, cellular, tissue, and organ-level phenomena—for example, linking insulin signaling pathways to whole-body glucose dynamics.

Multiscale and Multidisease Modeling

Researchers are developing multi-disease digital twins that account for comorbidities such as cardiovascular disease, kidney dysfunction, and obesity, which commonly accompany diabetes. Because these conditions interact in complex ways, a diabetes-specific digital twin may miss important effects. For instance, a patient with diabetic nephropathy may require different insulin clearance and sensitivity parameters than one with normal renal function. By integrating models of renal function, cardiac output, and lipid metabolism, a multidisease digital twin can provide a more comprehensive view of the patient’s health and guide treatment decisions that consider all aspects of their condition. This approach aligns with the broader vision of precision medicine, where care is tailored not just to a single disease but to the whole person.

Integration with AI and Closed-Loop Systems

In the longer term, digital twins could be coupled with closed-loop control systems to automate insulin delivery, diet suggestions, and activity recommendations in a continuous feedback loop. For example, a digital twin could run continuously on a smartphone or cloud server, ingesting CGM data, exercise data, and meal information in real time. When it predicts an impending hypoglycemic event, it could not only warn the patient but also automatically adjust the insulin pump’s basal rate or suggest a rescue carbohydrate through a smart speaker or wearable display. For type 2 diabetes, digital twins could be integrated with electronic health records to alert clinicians when a patient is trending toward worsening glycemic control or starting to develop complications. These advanced applications will require robust infrastructure, regulatory clearances, and validated algorithms that can safely operate in autonomous or semi-autonomous modes.

Toward Equitable Access and Global Deployment

To realize the full potential of digital twins for diabetes, the field must prioritize equitable access. This means designing affordable implementations that work without expensive proprietary hardware, developing models that are accurate across diverse populations, and ensuring that low-resource settings—where the diabetes burden is highest—are not left behind. Partnerships between academic institutions, device manufacturers, and regulatory bodies are critical to developing robust validation protocols and clinical implementation guidelines. Initiatives like the European Virtual Physiological Human (VPH Institute) and the Digital Twin Consortium are driving standardization and collaboration. Similarly, organizations such as the American Diabetes Association have begun to support research into digital twin applications through grants and conference sessions.

As computing power grows, data integration improves, and ethical frameworks solidify, digital twins are poised to become a cornerstone of personalized diabetes care. By providing a safe virtual space to test interventions and optimize therapy, they offer a path toward better glycemic control, fewer complications, and improved quality of life for millions of patients worldwide. The road ahead requires interdisciplinary collaboration, ethical vigilance, and a commitment to making these powerful tools accessible to all who need them. With continued investment and thoughtful deployment, digital twins will not only transform diabetes management but also serve as a model for how data-driven technology can personalize and improve care across many chronic conditions.